FIELD: chemistry.
SUBSTANCE: invention refers to the stable aqueous composition, which comprises hyaluronidase, the stabilizer for hyaluronidase and water as a solvent. Hyaluronidase is extracted from the testis of one or more mammals, excluding humans, and has the purity of 95 % or more and the specific activity of 70,000 IU/mg or more. Hyaluronidase stabilizer consists of the buffering agent for the provision of pH from 4.0 up to 6.0, the non-ionic surfactant from 0.001 up to 0.01 vol/vol% and from 0.1 up to 1 mM of ethylendiaminetetraacetic acid as the chelating agent or MgCl2. Hyaluronidase is purified from the hyaluronidase-containing material by means of application of affinity chromatography, ion exchange chromatography or gel filtration.
EFFECT: aqueous hyaluronidase composition of the invention is characterized by improved stability and can replace the lyophilized hyaluronidase compositions.
18 cl, 8 dwg, 21 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
EXTRACELLULAR HYALURONIDASE FROM Streptomyces koganeiensis | 2010 |
|
RU2553205C2 |
METHOD FOR PURIFYING VITAMIN K DEPENDENT PROTEINS SUCH AS COAGULATION FACTOR IX | 2011 |
|
RU2590726C2 |
METHOD OF PURIFYING VITAMIN K-DEPENDENT PROTEINS, SUCH AS COAGULATION FACTOR VII | 2011 |
|
RU2731720C2 |
METHOD OF ANTITROMBIN III MEDICATION PREPARATION OF HUMAN PLASMA | 2008 |
|
RU2357742C1 |
METHOD OF PURIFYING GROWTH FACTOR PROTEIN | 2011 |
|
RU2571926C2 |
METHOD OF PREPARING OF BIOLOGICALLY ACTIVE COMPONENTS | 0 |
|
SU1838406A3 |
HYALURONIDASE AND METHOD OF ITS APPLICATION | 2012 |
|
RU2608492C2 |
TREATMENT OF α-GALACTOSIDASE A INSUFFICIENCY | 2000 |
|
RU2248213C2 |
METHOD OF PRODUCING RECOMBINANT HYALURONIDASE | 2021 |
|
RU2822202C1 |
FUSION PROTEIN PURIFICATION METHOD | 2015 |
|
RU2698654C2 |
Authors
Dates
2018-03-19—Published
2013-08-05—Filed